Item 2. Properties
2K characters. Original on sec.gov · Markdown
Item 2. Properties
The Company's subsidiaries operate 61 manufacturing facilities occupying approximately 9.8 million square feet of floor space. The manufacturing facilities are used by the industry segments of the Company’s business approximately as follows:
| Segment | Square Feet (in thousands) | ||||
| Innovative Medicine | 5,026 | ||||
| MedTech | 4,782 | ||||
| Worldwide Total | 9,808 |
Within the U.S., five facilities are used by the Innovative Medicine segment and 18 by the MedTech segment. Outside of the U.S., 13 facilities are used by the Innovative Medicine segment and 25 by the MedTech segment.
The locations of the manufacturing facilities by major geographic areas of the world are as follows:
| Geographic Area | Number of Facilities | Square Feet (in thousands) | ||||||
| United States | 23 | 2,973 | ||||||
| Europe | 20 | 4,900 | ||||||
| Western Hemisphere, excluding U.S. | 5 | 692 | ||||||
| Africa, Asia and Pacific | 13 | 1,243 | ||||||
| Worldwide Total | 61 | 9,808 |
In addition to the manufacturing facilities discussed above, the Company maintains numerous office and warehouse facilities throughout the world.
The Company's subsidiaries generally seek to own, rather than lease, their manufacturing facilities, although some, principally in non-U.S. locations, are leased. Office and warehouse facilities are often leased. The Company also engages contract manufacturers.
The Company is committed to maintaining all of its properties in good operating condition.
Segment information on additions to property, plant and equipment is contained in Note 17 Segments of business and geographic areas of the Notes to Consolidated Financial Statements included in Item 8 of this Report.
Previous: Item 1C. Cybersecurity · Next: Item 3. Legal proceedings